Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression

Similar documents
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Value of Immunohistochemistry in StagingT1 Urothelial Bladder Carcinoma

+ use molecular testing to help drive my patients treatment plans.

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.

Staging and Grading Last Updated Friday, 14 November 2008

Beware the BCG Failures: A Review of One Institution's Results

Bladder Cancer Guidelines


BLADDER CANCER: PATIENT INFORMATION

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Multiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy

INTRAVESICAL THERAPY AND FOLLOW-UP OF SUPERFICIAL TRANSITIONAL CELL CARCINOMA OF THE BLADDER

Radical Cystectomy Often Too Late? Yes, But...

Urological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Issues in the Management of High Risk Superficial Bladder Cancer

Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy.

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

Disease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy

BLADDER CANCER CONTENT CREATED BY. Learn more at

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

Controversies in the management of Non-muscle invasive bladder cancer

Bladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope

Management of Superficial Bladder Cancer Douglas S. Scherr, M.D.

Bone Metastases in Muscle-Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC

Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy

Diagnosis and classification

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder

Urological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.

The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis

Symptoms, Diagnosis and Classification

MEDitorial March Bladder Cancer

Original Article APMC-276

The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study

When to Integrate Surgery for Metatstatic Urothelial Cancers

TUR-BT : transurethral resection of bladder tumor. 95 transitional cell carcinoma : Cytokeratin ; CK 8 11nm kD CK 1 8

Clinical Trials: Non-Muscle Invasive Bladder Cancer. Tuesday, May 17th, Part II

Bladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist

Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as a Spinal Cord Compression

Urological Tumours 1 Kidney tumours 2 Bladder tumours

Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression

Sino-nasal Cancer in Denmark 1982 ± 1991

Haematuria and Bladder Cancer

Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)

IMAGING OF UPPER UT TCC


The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

Efficient and Effective Use of Exfoliative Markers

Organ-sparing treatment of invasive transitional cell bladder carcinoma

The outcome of non-muscle invasive urinary bladder tumour at Makassed General Hospital

Bladder cancer - suspected

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER

The clinical epidemiology of superficial bladder cancer

Reviewer's report. Version:1Date:31 January Reviewer:IOANNIS LEOTSAKOS. Reviewer's report:

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis?

INVASIVE BLADDER CANCER

Glossary of Terms Primary Urethral Cancer

Comparative Analysis of Stage and Other Prognostic Factors Among Urethral, Ureteral, and Renal Pelvis Malignant Tumors

Care of bladder cancer patients diagnosed in Northern Ireland 2010 & 2011 (Summary)

Ivyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract

Upper Tract Tcc. Mohan Arianayagam FRACS (Urology)

BLADDER CANCER EPIDEMIOLOGY

Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience

A patient with recurrent bladder cancer presents with the following history:

BLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR

Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

A Review of Outcomes for Stage Ta Bladder Tumors

Afterword: The Paris System for Reporting Urinary Cytology

Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer

Citation for published version (APA): Cauberg, E. C. C. (2011). Advancements in diagnostic imaging for urothelial carcinoma.

Costing report: Bladder cancer

3.1 Investigations for Patients Presenting with Haematuria Table 1

Panel: A Case-based Approach to the Management of Bladder Cancer

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS

Guidelines for the Management of Bladder Cancer

비뇨병리연구회공청회 조남훈 연세대학교병리학교실

Update on Haematuria and Bladder Cancer

Prognostic value of the Gleason score in prostate cancer

Collection of Recorded Radiotherapy Seminars

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer

Carcinoma of the Renal Pelvis and Ureter Histopathology

MEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR BLADDER CANCER. POLICY NUMBER: CATEGORY: Technology Assessment

10/23/2012 CASE STUDIES: RENAL AND UROLOGIC IMPAIRMENTS. 1) Are there any clues from this history that suggest a particular diagnosis?

Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl

Transitional Cell Carcinoma of the Ureter: Prognostic Factors Influencing Progression and Survival

Renal tumors of adults

2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections

Patient Risk Profiles: Prognostic Factors of Recurrence and Progression

How Many Diseases in Carcinoma in situ?

Transcription:

BJU International (2), 85, 824±828 Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression K. ZIEGER, H. WOLF, P.R. OLSEN* and K. HéJGAARD{ Department of Urology, Aarhus University Hospital, Skejby, *Department of General Surgery, Holbñk Central Hospital and {Department of Pathology, Copenhagen University Hospital, Hvidovre, Denmark Objective To evaluate long-term recurrence-free and progression-free survival of noninvasive bladder tumours (stage Ta), and the signi cance of simple risk factors, including concomitant epithelial dysplasia. Patients and methods The study included 27 patients with primary noninvasive bladder tumour (stage Ta) who were followed routinely for up to 2 years. Voided urine cytology (VUC) and preselected site biopsies (PSB) were obtained prospectively to evaluate the signi cance of concomitant epithelial dysplasia. Results The mean follow-up was 84 months (maximum 238). Of all tumours, 39% did not relapse, a further 2% recurred infrequently (less than once a year) and 4% recurred frequently, amongst which the most frequent were multiple and early recurrent tumours; 42 (9%) tumours progressed to stage T+and 23 (%) progressed further (stage T2+or metastases). No grade tumours became invasive. Positive VUC or PSB, a short recurrence-free period or multiplicity, and size >3 cm were signi cant predictive factors. The treatment and surveillance of epithelium-con ned bladder tumours are discussed. Conclusion Concomitant dysplasia and early recurrence are associated with considerable risk of progression in the long-term follow-up in a group of otherwise lowrisk super cial bladder tumours (stage Ta). Keywords Bladder cancer, risk factors, recurrence, stage Ta, cytology, biopsy Introduction In a recent report we found lamina propria invasion to be the most signi cant prognostic factor for the long-term survival of so-called `super cial' urinary bladder tumours; 85±9% of patients with initial Ta tumours, but only a third of those with lamina propria invasion (stage T) nally survived their disease []. This perception is not new and has been con rmed by many others [2±5]. Nevertheless, only a few studies provided a separate follow-up for this low-risk group of tumours [6,7]. However, a ±5% nal risk of progression, eventually leading to death from cancer, is not negligible. Several prognostic factors have been indicated, but little is known about their long-term signi cance and only a few are applied for treatment and surveillance decisions in routine practice [3]. The grade of dysplasia, size and multiplicity of the tumours, the presence/absence of concomitant epithelial dysplasia/ carcinoma in situ (CIS) and the recurrence rate or time to rst recurrence are signi cant prognostic factors, accessible by simple endoscopic and microscopic examination, and well-known for many years [3]. The present series of patients with bladder cancer were enrolled in 976 to Accepted for publication 4 December 999 investigate the impact of concomitant epithelial changes [8]. To our knowledge, no report has yet con rmed the long-term signi cance of this important prognostic factor. In the present study we followed low-risk patients (stage Ta) for up to 2 years, and assessed recurrenceand progression-free survival. Patients and methods Of a series of 584 consecutive, unselected patients admitted for newly diagnosed urinary bladder tumour to one hospital in Copenhagen, 24 had Ta disease; 27 (54 men, mean age 66 years, range 34±84, and 63 women, mean age 67 years, range 2±87) were followed for at least one year and included for evaluation. Tumours were graded following the Bergkvist classi cation [9]. Voided urine cytology (VUC, 83%) and preselected site biopsies (PSB, 87%) were obtained prospectively according to the procedure described previously [8], the results having no in uence on the management of the patients. The samples were graded using the same method and regarded as positive when at least one positive specimen was obtained. Any suspect cells were regarded as positive. The treatment (including that for super cial recurrence) was TURBT. Ten patients received supplementary 824 # 2 BJU International

FOLLOW-UP OF NONINVASIVE BLADDER TUMOURS 825 intravesical chemotherapy (thiotepa), retinoid was given in nine patients (with no effect) and radiotherapy in two. One tumour was detected incidentally during transvesical prostatectomy and resected. Four patients were treated with intravesical BCG (after 987). Patients were followed by cystoscopy every fourth month. The time to rst recurrence (observed recurrence-free period, RFP) and the recurrence rate (RR) were determined as distinct end-points. For the RR, the number of relapses was counted, so that multiple relapses corresponded to single occurrences at reduced control intervals. `Flat papillomatosis' was counted as one recurrence. The RR was de ned as (no relapses observed), (< relapse per year) or 2 (o relapses per year) and encompassed the total follow-up up to 2 years. `Conversion' was de ned as progression in grade with no invasion; `progression' was de ned as progression in stage, i.e. invasion of the lamina propria or deeper (T+), or distant metastases. T tumours were treated by TURBT, but one open bladder resection and two cystectomies were performed, and ve patients received full-course radiotherapy when muscle invasion (T2+) occurred. The routine follow-up was continued to a RFP of 5 years. Some patients continued voluntarily or were readmitted with relapses later. The hospital les were reviewed for all those patients who ceased follow-up at some time. If the patient moved from the area, the hospitals taking the patients were contacted for further data. The mean follow-up was 84 months (maximum 238). The nal status was obtained by autopsy or laparotomy in 7 patients (33%) and by cystoscopy or relevant radiological imaging (metastases) in 46 (66%); 59 patients (26%) were alive at the end of the study ( January 997) and were censored at the time of their last control cystoscopy. In the statistical evaluation the log-rank test and Cox regression analysis model were applied where indicated [] and differences regarded as signi cant when P<.5. Results The initial tumour characteristics are shown in Table, given as the Bergkvist grade of dysplasia, which is recognized as one of the major determinants of malignancy [3,9]. There was a close positive correlation between grade, multiplicity, size of tumour, and the results of VUC and PSB. Of all tumours, 6% recurred (Fig. a). After a RFP of one year, the cumulative probability was 46%, and after a RFP of 2 years it was 34%. In 85 patients (39%) there was no recurrence (RR ) and another 43 patients (2%) had less than one recurrence per year (RR ); 4% of the tumours recurred frequently (RR 2). After a RFP of one year the probability of frequent recurrence was 6% and after 2 years it was 6%. Of 89 tumours with a RR of 2, 8% had recurred within one year and 9% within 2 years. If the tumour had recurred within one year, it continued to recur (RR 2) in 84%. Five patients were readmitted after a RFP of >5 years; two of these had a RR of 2, corresponding to 5% of 38 who survived 5 years with no recurrence. In the multiple Cox regression analysis of risk factors (Table 2), tumour multiplicity, size and urine cytology, in descending order, were independent signi cant variables predicting recurrence, but the grade of dysplasia was not, because it was correlated with the other factors (Table ). Forty-two tumours (9%) had invasive potential; 9 of these were limited to stage T, but 23 (%) showed muscle-invasion (T2+) or distant metastases. Twentythree patients died from bladder cancer-related causes, including three with no apparent muscle invasion. The cause-speci c survival rate was equal to that reported for the initial T tumours []. None of the grade tumours progressed but six converted to grade 2; Ta grade 2 tumours converted Table Characteristics of 27 consecutive, unselected noninvasive bladder tumours (Ta category) graded using the Bergkvist method. Differences in totals (last column) were caused by the item not being evaluable or not determined. Percentages are given in brackets Characteristic n (%) Grade / 2 3 Total Single 29 (88) 35 (76) 2 66 Multiple 4 43 3 5 <3 cm 3 (9) 37 (77) 3 7 >3 cm 3 4 2 46 VUC negative 25 (86) 95 (66) 2 positive 4 5 4 58 PSB negative 26 () 33 (84) 3 62 positive 26 27 Total 33 79 5 27 # 2 BJU International 85, 824±828

826 K. ZIEGER et al. to Ta grade 3 (three) or CIS (seven), with later progression in ve of the latter. Forty-one Ta grade 2 tumours (23%) and one of ve Ta grade 3 tumours progressed in stage (T+). Progression occurred after a mean (range) of 55 (3±29) months. Four tumours progressed with no previous benign recurrences. The progression-free survival (T+and T2+) for Ta tumours is shown in Fig. b. The progression rate was approximately constant over the observation period, i.e. there were many late progressions. a..8.6.4.2 b..8.6.4.2 c..8.6.4.2 2 3 4 5 6 7 8 9 Follow-up period (years) 2 3 4 5 6 7 8 9 2 3 4 5 Follow-up period (years) 2 3 4 5 6 7 8 9 2 3 4 5 Observation time (years) Fig.. Kaplan±Meier plot of the cumulative probability of: a, recurrence for Ta tumours; b, lamina propria invasion (green) and muscle-invasion or metastases (red) for Ta tumours; and c, progression (in T+) for Ta tumours in a combined analysis of major risk factors (84 patients at low-risk, PSB + VUC ±ve, RFP > year, green; 92 patients PSB or VUC +ve, or RFP < year, light green; 4 patients at high-risk, PSB or VUC +ve and time to recurrence < year, red). In all, the 95% CI are indicated as stippled lines. Positive VUC, positive PSB, a RFP of < year, tumour size and multiplicity (all P<.) were predictive of progression in the log-rank test. Multiple regression analysis showed that RFP, VUC and size, in descending order of signi cance, were independent factors predicting future progression (Table 2). There was a close correlation between the effects of VUC and PSB, and between RFP and multiplicity on the progression rate. For progression to muscle invasion (T2+) only VUC and the RFP were independent signi cant factors, because there were fewer events (23). Only two of 84 patients with initially negative VUC/ PSB and a RFP of > year progressed; none of the tumours became muscle invasive; 92 patients with one factor positive and 4 with both factors positive had progression rates to muscle invasion of 2% and 5% after 5 years, respectively (Fig. c). For comparison, all patients with CIS (dysplasia grade 3), including primary CIS with symptoms (seven), concomitant CIS with Ta grade 2 or 3 (three), and CIS with previous Ta grade 2 tumour (conversion, seven) were also reviewed. In all the patients with CIS, tumours developed later; of 7 progressed to invasive TCC, seven of whom progressed to advanced disease (T2+). As the need for routine IVU in the follow-up of super cial bladder tumours is contentious [4,,2], the incidence of upper urinary tract TCC (UTT) was examined retrospectively in the present series of patients at low-risk after the long-term follow-up. Fifteen patients (7%) had UTT (seven in the renal pelvis, three in the ureter and ve with multiple tumours); nine tumours were invasive (T+). The tumours were found after a mean of 52 months. Frequently recurrent bladder tumours accompanied all but two UTT; these two tumours were found incidentally and were the only tumours detected > years (6 and 28 months) after the diagnosis of the primary bladder tumour; neither was treated. Discussion This study presents the natural history of 27 unselected, newly diagnosed, noninvasive bladder tumours with up to 2 years of follow-up under conservative treatment. The conditions for long-term follow-up in Scandinavian countries are excellent, because there is a stable society, a central population register and a public health system covering nearly all the population. If contact is lost, the patients are easy to track in the register and are likely to be identi ed from the les of their local hospital if they have any health problems. This enabled the present review to be based on objective data with little `loss to follow-up'. Knowledge of the long-term natural history of super- cial bladder tumours is increasing [2±5]. Unfortunately, # 2 BJU International 85, 824±828

FOLLOW-UP OF NONINVASIVE BLADDER TUMOURS 827 Table 2 The test for equality of distribution of recurrence and progression for Ta tumours in a multiple regression analysis model containing the signi cant predictive variables multiplicity, size, histological grade, VUC, PSB and RFP. b is the estimate of the regression coef cient and P the probability Variable Wald value b (SE) P Recurrence Multiplicity.8 x.7 (.2).9 Size 7.4 x.62 (.23).7 Grade.66 x.24 (.3).4 VUC 5.5 x.46 (.2).2 Progression VUC 7.54 x.7 (.43).6 PSB.5 x.42 (.4).3 RFP 9.8.58 (.5).2 Mult..23 x.42 (.37).27 Size 5.5 x.88 (.37).2 not many authors consequently distinguish between Ta and T categories. The probability of recurrence for Ta tumours is concordantly reported to be < 6% [3,7]. There is broad agreement that multiple tumours and tumours with a history of recurrences are most likely to relapse. The disease-free interval after primary diagnosis is clearly signi cant for the frequency of future recurrences [3,5,3]. In the present study there was no bene t of prolonged surveillance after a RFP of 2 years for the detection of frequently recurrent or progressive disease. The estimation of the probability of progression requires a long-term follow-up; there are few reports assessing lowrisk (stage Ta) super cial bladder tumours. Prout et al. [7] followed 78 patients with Ta grade (WHO) tumours for up to years. Progression rates were 3% (T+) and 2% (T2+), respectively; the authors emphasized that these tumours were not distinguishable initially from others, but there were few progression events. A combined follow-up study of 576 Ta/T tumours from EORTC randomized trials reported a progression rate of 9% (T2+) for 3 Ta tumours after a median follow-up of 4 years [5]. The authors used a multivariate analysis of risk factors, including size, multiplicity, grade, stage, site and recurrence. Except for grade, which is closely correlated with stage, the RFP/previous RR and tumour size were independently signi cant. Cytology and/or PSB results were not assessed. However, as T and nonprimary tumours were included, the results are not directly comparable with the present, study. The Swedish study by Holmang et al. [4] is more comparable, as it was also Scandinavian with a long follow-up based on objective data and tumours were graded using the same system [9], which is based on cellular pattern. There were fewer patients but with a longer and more intense follow-up. The high progression rate of 4% (crude) is thus comparable with the present, but the exclusion of concomitant CIS (two) and those undergoing more aggressive treatment (six cystectomies and three radiotherapy in 77 patients; present study, two radiotherapy in 27) reduced the number of high-risk patients in the follow-up. Interestingly, the progression of three Bergkvist grade tumours was reported. There was no progression in this group in the present patients, despite ve having frequent recurrences. It is also remarkable that the (few) grade 3 tumours had a progression rate that was no higher than in grade ±2 tumours, which is consistent with the present results. Concomitant dysplasia was not addressed by Holmang et al. Cookson et al. [2] reported the long-term follow-up of 86 high-risk patients with Ta/T tumours. The progression rate was 53%, similar to that for the highrisk group of present Ta tumours. As in the EORTC study, randomized patients were followed, biasing the follow-up to younger patients and high survival rates. Although the authors recognized lamina propria invasion, concomitant CIS and multiple recurrences as high-risk factors, they did not separate these factors in their analysis. Indeed, for the present Ta category, positive VUC was a very signi cant prognostic factor and it is likely that the neoplastic cells derive from CIS rather than from the benign Ta tumours [4]. Positive VUC correctly and signi cantly predicted the malignant nature of disease which lead to progression 5±5 years later. Urine cytology is not speci c; half of the present 58 patients with initial positive VUC neither converted nor progressed. Thus, random or preselected site biopsies have been evaluated. Positive biopsies predict recurrence [3], but most tumours with negative samples also recur. PSB were no more speci c than VUC in predicting progression and the sensitivity was low (85%). Concomitant CIS with Ta tumour is rarely found in PSB; intraepithelial dysplasia grade 2 is more common (< 5%), but its signi cance is dubious. Thus, PSB are dispensable as a routine procedure. However, the combined analysis of # 2 BJU International 85, 824±828

828 K. ZIEGER et al. the VUC and PSB results had more signi cance; the risk of progression was equivalent to native CIS. Nevertheless, as not all tumours with invasive potential could have been diagnosed at the initial evaluation, repeated samples and control investigations are necessary. The results indicate that there should be more weight placed on the results of VUC and PSB sampling when deciding the therapy for Ta disease. VUC samples should be obtained initially and at every follow-up assessment. PSB should be taken if the VUC is positive. Any dysplasia indicates a treatment equivalent to CIS, i.e. instillation of BCG/mitomycin C, and cystectomy if the therapy fails. Treatment may also be considered if VUC is repeatedly positive. Control assessments should continue until a RFP of 2 years. Frequent recurrences demand intense surveillance, but may safely be treated by TURBT alone, unless positive VUC/PSB samples indicate a more aggressive approach. IVU may be justi ed in these patients as part of the follow-up, but the validity of routine exposures to detect UTT is doubted. Patients with Ta bladder tumours, especially when single and small at diagnosis, may be discharged after 2 years with no recurrence or positive VUC. Their risk of frequent recurrence, CIS, invasive bladder cancer or UTT is little higher than in the general population. Recurrence will occur occasionally in some cases but the informed patient may safely be followed by their GP with haematuria dipstick and VUC evaluation annually, with minimum discomfort [5,6]. This will be valid for < 4% of all newly diagnosed Ta tumours. Acknowledgements Thanks to Vestdansk Sundhedsvidenskabeligt Forskningsforums Konsulenttjeneste for help with the statistical work, and to Fru Agnes Niebuhr Anderssons Cancer forskningsfond for nancial support. References Zieger K, Wolf H, Olsen PR, Hùjgaard K. Long term followup of bladder tumours: the signi cance of risk factors. Br J Urol 998; 82: 667±72 2 Abel PD. Follow-up of patients with `super cial' transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol 993; 72: 35±42 3 Heney NM. Natural history of bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 992; 9: 429±33 4 Holmang S, Hedelin H, AnderstroÈm C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stage Ta and T transitional cell cancer of the bladder followed for at least 2 years. J Urol 995; 53: 823±7 5 Kurth KH, Denis L, Bouf oux C et al. Factors affecting recurrence and progression in super cial bladder tumours. Eur J Cancer 995; 3: 84±6 6 AnderstroÈm C, Johansson S, Nilsson S. The signi cance of lamina propria invasion on the prognosis of patients with bladder tumours. J Urol 98; 24: 23±6 7 Prout GR, Barton BA, Grif n PP, Friedell GH. Treated history of noninvasive grade transitional cell carcinoma. J Urol 992; 48: 43±9 8 Wolf H, Hùjgaard K. Urothelial dysplasia in random mucosal biopsies from patients with bladder tumours. Scand J Urol Nephrol 98; 4: 37±4 9 Bergkvist A, Ljungkvist A, Moberger G. Classi cation of bladder tumours based on a cellular pattern. Acta Chir Scand 965; 3: 37±8 Cox DR. Regression models and life tables. J Roy Stat Soc B 972; 34: 87±22 Hurle R, Losa A, Manzetti A, Lembo A. Upper urinary tract tumours developing after treatment of super cial bladder cancer: 7 year follow-up of 59 consecutive patients. Urology 999; 53: 45±8 2 Cookson MS, Herr HW, Zhang Z, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk super cial bladder cancer: 5-year outcome. J Urol 997; 58: 62±7 3 Morris SB, Gordon EM, Shearer RJ, Woodhouse CRJ. Super cial bladder cancer: for how long should a tumourfree patient have check-cystoscopies? Br J Urol 995; 75: 93±6 4 Harving N, Wolf H, Melsen F. Positive urinary cytology after tumour resection: an indicator for concomitant carcinoma in situ. J Urol 988; 4: 495±7 5 Meuleman EJH, Delaere KPJ. Diagnostic ef cacy of the combination of cytology, urine analysis and history in the follow-up of bladder carcinoma. Br J Urol 988; 62: 5±3 6 Soloway MS, Murphy WM, Johnson DE, Farrow GM, Paulson DF, Garnick MB. Initial evaluation and response criteria for patients with super cial bladder cancer. Report of a workshop. Br J Urol 99; 66: 38±5 Authors K. Zieger, MD. H. Wolf, MD, PhD. P.R. Olsen, MD, PhD. K. Hùjgaard, MD. Correspondence: Lñge Karsten Zieger, Skovvej 27, Gram DK 866 Skanderborg, Denmark. # 2 BJU International 85, 824±828